This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Markers to predict non-responders to interferon- α and ribavirin treatment for HCV	<p>A human genetic study suggests genotyping for <i>IL-28B</i> (<i>IL28B</i>; <i>IFNL3</i>) and major histocompatibility complex class I C (<i>HLA-C</i>) could help predict nonresponders to the HCV therapies interferon-α and ribavirin. In a European cohort infected with HCV, genotyping of <i>IL28B</i> and <i>HLA-C</i> predicted treatment failure better than either marker alone. Next steps could include identifying further genetic associations.</p> <p>SciBX 4(38); doi:10.1038/scibx.2011.1079 Published online Sept. 29, 2011</p>	Patent application filed for method to determine response to treatment with immunomodulatory composition; available for licensing from the University of Sydney	<p>Suppiah, V. <i>et al. PLoS Med.</i>; published online Sept. 13, 2011; doi:10.1371/journal.pmed.1001092</p> <p>Contact: David Booth, Institute for Immunology and Allergy Research, Sydney, New South Wales, Australia e-mail: david_booth@wmi.usyd.edu.au</p>